Ebos GroupASX:EBO +3.13%77 PS Ratio is 0.27 as of Jul. 04, 2026, which is 45% below its 10-year median of 0.49. GuruFocus rates ASX:EBO with a GF Score™ of 77/100 and a GF Value™ of A$31.51 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 116 Medical Distribution companies, Ebos Group ranks better than 60.34% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Ebos Group's share price is A$17.47.
Ebos Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$63.74. Hence, Ebos Group's PS Ratio for today is 0.27.
Good Sign:
Ebos Group Ltd stock PS Ratio (=0.31) is close to 10-year low of 0.29.
The historical rank and industry rank for Ebos Group's PS Ratio or its related term are showing as below:
ASX:EBO'
s PS Ratio Range Over the Past 10 Years
Min: 0.29 Med: 0.49 Max: 0.72
Current: 0.3
During the past 13 years, Ebos Group's highest PS Ratio was 0.72. The lowest was 0.29. And the median was 0.49.
ASX:EBO's PS Ratio is ranked better than 60.34% of 116
companies
in the Medical Distribution industry
Industry Median: 0.415
vs ASX:EBO: 0.30
Ebos Group Ltd revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Ebos Group was -1.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -0.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 4.10% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 5.80% per year.
During the past 13 years, Ebos Group's highest 3-Year average Revenue per Share Growth Rate was 45.20% per year. The lowest was -0.70% per year. And the median was 9.90% per year.
Back to Basics: PS Ratio
Ebos Group (ASX:EBO) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Ebos Group PS Ratio Related Terms
Ebos Group PS Ratio Historical Data
* Premium members only.
The historical data trend for Ebos Group's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Ebos Group's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ebos Group PS Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ebos Group's PS Ratio distribution charts can be found below:
* The bar in red indicates where Ebos Group's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Ebos Group's Share Price of today is A$17.47.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ebos Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$63.74.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Ebos Group (ASX:EBO) has a PS Ratio of 0.27 as of Jul. 04, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Ebos Group and its competitors. This is 45% below median its historical median of 0.49. Over the past decade, Ebos Group's PS Ratio has ranged from 0.29 to 0.72. According to the industry distribution chart, Ebos Group ranks #46 out of 116 companies in the Medical Distribution industry, placing it in the top 39.7%.
Is Ebos Group's PS Ratio too high?
Ebos Group's current PS Ratio of 0.27 is 45% below median its 10-year median of 0.49. Over the past 10 years, this metric has ranged from a low of 0.29 to a high of 0.72. The Medical Distribution industry median PS Ratio is 0.42. Ebos Group's value of 0.27 is 34.9% below this industry median. Based on the distribution chart, Ebos Group ranks #46 out of 116 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Ebos Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ebos Group's PS Ratio compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Ebos Group ranks #46 out of 116 companies for PS Ratio. This puts Ebos Group in the upper half of its industry. The industry median PS Ratio is 0.42. Ebos Group's value of 0.27 is 34.9% below this benchmark. Historically, Ebos Group's own PS Ratio has ranged from 0.29 to 0.72 over the past decade. While the company's 10-year median is 0.49 vs. the industry median of 0.42, Ebos Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Distribution company?
The median PS Ratio among Medical Distribution companies is 0.42, based on 116 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ebos Group's current PS Ratio of 0.27 is 34.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Ebos Group and its competitors. For the Medical Distribution industry, the median PS Ratio is 0.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ebos Group's current PS Ratio is 0.27, which is 45% below median its own 10-year median of 0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ebos Group stock overvalued right now?
Based on GuruFocus' analysis, Ebos Group (ASX:EBO) is currently considered Significantly Undervalued. The stock's GF Value™ is A$31.51, compared to a current price of A$17.47 — trading 44.6% below its estimated fair value. The current PS Ratio is 0.27, which is 45% below median its 10-year median of 0.49 and 34.9% below the Medical Distribution industry median of 0.42. Ebos Group's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Ebos Group (ASX:EBO), the current PS Ratio is 0.27 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ebos Group (ASX:EBO) Overvalued in 2026?
Based on GuruFocus' analysis, Ebos Group stock appears to be undervalued.
The current stock price of A$17.47 is trading 44.6% below its estimated GF Value™ of A$31.51.
GuruFocus considers Ebos Group to be Significantly Undervalued.
Key valuation signals for ASX:EBO:
PS Ratio: 0.27 (45% below median its 10-year median of 0.49)
GF Value™: A$31.51 vs. price of A$17.47 (44.6% below fair value)
Industry Position: 34.9% below the Medical Distribution median (#46 of 116)
No single metric tells the full story. See the ASX:EBO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ebos is the largest pharmaceutical wholesaler across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 50% and 30% of revenue, respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government's Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low-single-digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.
77GF Score
Get the complete analysis for ASX:EBO
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EBO has been successfully added to your 
